-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target

Benzinga·03/03/2025 14:57:19
Listen to the news
Citizens Capital Markets analyst Jonathan Wolleben reiterates BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and maintains $18 price target.